First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [(68)Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
Journal Title
Journal of Nuclear Medicine
Publication Type
Online publication before print
Abstract
[(68)Ga]Ga-DPI-4452, a first-in-class carbonic anhydrase IX-binding radiolabeled peptide, is the imaging agent of a theranostic pair with [(177)Lu]Lu-DPI-4452, developed for selecting and treating patients with carbonic anhydrase IX-expressing tumors. Here, [(68)Ga]Ga-DPI-4452 imaging characteristics, dosimetry, pharmacokinetics, and safety were assessed in 3 patients with clear cell renal cell carcinoma. Methods: After [(68)Ga]Ga-DPI-4452 administration, patients underwent serial full-body PET/CT imaging. Blood and urine were sampled. Safety was monitored for 7 d after injection. Results: Tumor uptake was observed at all time points (15 min to 4 h). Across 36 lesions, the SUV(max) at 1 h after administration ranged from 6.8 to 211.6 (mean, 64.6 [SD, 54.8]). The kidneys, liver, and bone marrow demonstrated low activity. [(68)Ga]Ga-DPI-4452 was rapidly eliminated from blood and urine. No clinically significant toxicity was observed. Conclusion: [(68)Ga]Ga-DPI-4452 showed exceptional tumor uptake in patients with clear cell renal cell carcinoma, with very high tumor-to-background ratios and no significant adverse events, suggesting potential diagnostic and patient selection applications.
Keywords
Pet/ct; [68Ga]Ga-DPI-4452; clear cell renal cell carcinoma; theranostic
Department(s)
Cancer Imaging; Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.2967/jnumed.123.267175
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-04-02 04:06:04
Last Modified: 2024-04-02 04:14:45

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙